| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
| ln Vitro |
The immune systems, baldness, stooped posture, and vulnerability to aortic aneurysms are all present in mice pups that are born and nursed by moms deficient in pyrroloquinoline quinone (PQQ) [2].
|
|---|---|
| References | |
| Additional Infomation |
Pyrroloquinoline quinone is a pyrroloquinoline compound with carbonyl groups at positions 4 and 5, and carboxyl groups at positions 2, 7, and 9. It functions as a water-soluble vitamin, cofactor, antioxidant, and anti-inflammatory agent. It is an ortho-quinone compound, a tricarboxylic acid, and a pyrroloquinoline cofactor. It is the conjugate acid of pyrroloquinoline quinone (3-). Pyrroloquinoline quinone is a metabolite found or produced in Escherichia coli (strains K12 and MG1655). It has also been reported to be found in Hyphomicrobium, with relevant data available. A pyrroloquinoline compound with two adjacent ketone groups and three acidic carboxyl groups at positions 4 and 5, respectively. It is a coenzyme for certain dehydrogenases.
|
| Molecular Formula |
C14H6N2O8
|
|---|---|
| Molecular Weight |
330.2060
|
| Exact Mass |
330.012
|
| CAS # |
72909-34-3
|
| PubChem CID |
1024
|
| Appearance |
Pink to red solid powder
|
| Density |
2.0±0.1 g/cm3
|
| Boiling Point |
1018.6±65.0 °C at 760 mmHg
|
| Flash Point |
569.8±34.3 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.801
|
| LogP |
-0.65
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
24
|
| Complexity |
647
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
MMXZSJMASHPLLR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H6N2O8/c17-10-4-2-6(14(23)24)15-8(4)7-3(12(19)20)1-5(13(21)22)16-9(7)11(10)18/h1-2,15H,(H,19,20)(H,21,22)(H,23,24)
|
| Chemical Name |
4,5-dioxo-1H-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~1 mg/mL (~3.03 mM)
DMSO :< 1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 1 mg/mL (3.03 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication (<60°C).
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0284 mL | 15.1419 mL | 30.2838 mL | |
| 5 mM | 0.6057 mL | 3.0284 mL | 6.0568 mL | |
| 10 mM | 0.3028 mL | 1.5142 mL | 3.0284 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
